Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11 - 30; http://dx.doi.org/10.3322/caac.21166; PMID: 23335087
   PubMed Web of Science ®Google Scholar
• Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nature reviews. Clin Oncol 2012; 9:135 - 43
   Web of Science ®Google Scholar
• De Raeve HR, Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 2005; 20:1227 - 50; PMID: 16136504
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123:1542 - 55; http://dx.doi.org/10.1172/JCI66517; PMID: 23454749
   PubMed Web of Science ®Google Scholar
• Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2007; 21:1079 - 88
   PubMed Web of Science ®Google Scholar
• Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res 2012; 18:342 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-11-2212; PMID: 22065077
   PubMed Web of Science ®Google Scholar
• Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005; 7:499 - 500; http://dx.doi.org/10.1016/j.ccr.2005.05.019; PMID: 15950897
   PubMed Web of Science ®Google Scholar
• Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009; 25:30 - 8; http://dx.doi.org/10.1016/j.tig.2008.10.012; PMID: 19054589
   PubMed Web of Science ®Google Scholar
• Weinberg RA. Coevolution in the tumor microenvironment. Nat Genet 2008; 40:494 - 5; http://dx.doi.org/10.1038/ng0508-494; PMID: 18443582
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335 - 48; http://dx.doi.org/10.1016/j.cell.2005.02.034; PMID: 15882617
   PubMed Web of Science ®Google Scholar
• Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32:303 - 15; http://dx.doi.org/10.1007/s10555-012-9415-3; PMID: 23114846
   PubMed Web of Science ®Google Scholar
• Haviv I, Polyak K, Qiu W, Hu M, Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009; 8:589 - 95; http://dx.doi.org/10.4161/cc.8.4.7669; PMID: 19182519
   PubMed Web of Science ®Google Scholar
• Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4:e4992; http://dx.doi.org/10.1371/journal.pone.0004992; PMID: 19352430
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009; 69:1255 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-08-3562; PMID: 19208837
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70:6945 - 56; http://dx.doi.org/10.1158/0008-5472.CAN-10-0785; PMID: 20699369
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990; 87:7235 - 9; http://dx.doi.org/10.1073/pnas.87.18.7235; PMID: 2402505
   PubMed Web of Science ®Google Scholar
• Cheng JD, Dunbrack RL Jr., Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002; 62:4767 - 72; PMID: 12183436
   PubMed Web of Science ®Google Scholar
• Shi W, Liu J, Li M, Gao H, Wang T. Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors. Curr Eye Res 2010; 35:967 - 77; http://dx.doi.org/10.3109/02713683.2010.502294; PMID: 20958185
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004; 64:2712 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-03-3184; PMID: 15087384
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330:827 - 30; http://dx.doi.org/10.1126/science.1195300; PMID: 21051638
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, Wang Z. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011; 303:47 - 55; http://dx.doi.org/10.1016/j.canlet.2011.01.011; PMID: 21310528
   PubMed Web of Science ®Google Scholar
• Huang Y, Simms AE, Mazur A, Wang S, León NR, Jones B, Aziz N, Kelly T. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011; 28:567 - 79; http://dx.doi.org/10.1007/s10585-011-9392-x; PMID: 21604185
   PubMed Web of Science ®Google Scholar
• Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005; 42:935 - 45; http://dx.doi.org/10.1002/hep.20853; PMID: 16175601
   PubMed Web of Science ®Google Scholar
• Jacob M, Chang L, Puré E. Fibroblast activation protein in remodeling tissues. Curr Mol Med 2012; 12:1220 - 43; http://dx.doi.org/10.2174/156652412803833607; PMID: 22834826
   PubMed Web of Science ®Google Scholar
• Fischer E, Chaitanya K, Wüest T, Wadle A, Scott AM, van den Broek M, Schibli R, Bauer S, Renner C. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res 2012; 18:6208 - 18; http://dx.doi.org/10.1158/1078-0432.CCR-12-0644; PMID: 22992515
   PubMed Web of Science ®Google Scholar
• Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276:71 - 4; http://dx.doi.org/10.1126/science.276.5309.71; PMID: 9082988
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143 - 7; http://dx.doi.org/10.1126/science.284.5411.143; PMID: 10102814
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418:41 - 9; http://dx.doi.org/10.1038/nature00870; PMID: 12077603
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315 - 7; http://dx.doi.org/10.1080/14653240600855905; PMID: 16923606
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25:2739 - 49; http://dx.doi.org/10.1634/stemcells.2007-0197; PMID: 17656645
   PubMed Web of Science ®Google Scholar
• Rettig WJ, Chesa PG, Beresford HR, Feickert HJ, Jennings MT, Cohen J, Oettgen HF, Old LJ. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res 1986; 46:6406 - 12; PMID: 2877731
   PubMed Web of Science ®Google Scholar
• Rettig WJ, Spengler BA, Chesa PG, Old LJ, Biedler JL. Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res 1987; 47:1383 - 9; PMID: 3028608
   PubMed Web of Science ®Google Scholar
• Aoyama A, Chen WT. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci U S A 1990; 87:8296 - 300; http://dx.doi.org/10.1073/pnas.87.21.8296; PMID: 2172980
   PubMed Web of Science ®Google Scholar
• Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, Chen WT. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994; 54:5702 - 10; PMID: 7923219
   PubMed Web of Science ®Google Scholar
• Mathew S, Scanlan MJ, Mohan Raj BK, Murty VV, Garin-Chesa P, Old LJ, Rettig WJ, Chaganti RS. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995; 25:335 - 7; http://dx.doi.org/10.1016/0888-7543(95)80157-H; PMID: 7774951
   PubMed Web of Science ®Google Scholar
• Piñeiro-Sánchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Tran H, Argraves WS, Chen WT. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997; 272:7595 - 601; http://dx.doi.org/10.1074/jbc.272.12.7595; PMID: 9065413
   PubMed Web of Science ®Google Scholar
• Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A 1988; 85:3110 - 4; http://dx.doi.org/10.1073/pnas.85.9.3110; PMID: 2896356
   PubMed Web of Science ®Google Scholar
• Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993; 53:3327 - 35; PMID: 8391923
   PubMed Web of Science ®Google Scholar
• Kelly T, Kechelava S, Rozypal TL, West KW, Korourian S. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc 1998; 11:855 - 63
   Google Scholar
• Mori Y, Kono K, Matsumoto Y, Fujii H, Yamane T, Mitsumata M, Chen WT. The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology 2004; 67:411 - 9; http://dx.doi.org/10.1159/000082926; PMID: 15713998
   PubMed Web of Science ®Google Scholar
• Mentlein R, Hattermann K, Hemion C, Jungbluth AA, Held-Feindt J. Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors. Biol Chem 2011; 392:199 - 207; http://dx.doi.org/10.1515/bc.2010.119; PMID: 20707604
   PubMed Web of Science ®Google Scholar
• Acharya PS, Zukas A, Chandan V, Katzenstein AL, Puré E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 37:352 - 60; http://dx.doi.org/10.1016/j.humpath.2005.11.020; PMID: 16613331
   PubMed Web of Science ®Google Scholar
• Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Gödde S, Dinges H, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8:R171; http://dx.doi.org/10.1186/ar2080; PMID: 17105646
   PubMed Web of Science ®Google Scholar
• Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29:1768 - 78; http://dx.doi.org/10.1002/hep.510290631; PMID: 10347120
   PubMed Web of Science ®Google Scholar
• Bae S, Park CW, Son HK, Ju HK, Paik D, Jeon CJ, Koh GY, Kim J, Kim H. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br J Haematol 2008; 142:827 - 30; http://dx.doi.org/10.1111/j.1365-2141.2008.07241.x; PMID: 18510677
   PubMed Web of Science ®Google Scholar
• Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 2007; 86:8 - 16; http://dx.doi.org/10.1532/IJH97.06230; PMID: 17675260
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68:4331 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-0943; PMID: 18519693
   PubMed Web of Science ®Google Scholar
• Garayoa M, Garcia JL, Santamaría C, Garcia-Gomez A, Blanco JF, Pandiella A, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2009; 23:1515 - 27; http://dx.doi.org/10.1038/leu.2009.65
   PubMed Web of Science ®Google Scholar
• Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2007; 21:158 - 63; http://dx.doi.org/10.1038/sj.leu.2404466
   PubMed Web of Science ®Google Scholar
• Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2009; 23:1515 - 27; http://dx.doi.org/10.1038/leu.2009.65
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007; 25:2648 - 59; http://dx.doi.org/10.1634/stemcells.2007-0226; PMID: 17615264
   PubMed Web of Science ®Google Scholar
• Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24:986 - 91; http://dx.doi.org/10.1634/stemcells.2005-0220; PMID: 16293576
   PubMed Web of Science ®Google Scholar
• Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 2012; 30:266 - 79; http://dx.doi.org/10.1002/stem.787; PMID: 22102554
   PubMed Web of Science ®Google Scholar
• Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol 2012; 158:336 - 46; http://dx.doi.org/10.1111/j.1365-2141.2012.09154.x; PMID: 22583117
   PubMed Web of Science ®Google Scholar
• Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005; 106:713 - 6; http://dx.doi.org/10.1182/blood-2005-01-0373; PMID: 15817674
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer 2010; 9:176; http://dx.doi.org/10.1186/1476-4598-9-176; PMID: 20604947
   PubMed Web of Science ®Google Scholar
• Corre J, Labat E, Espagnolle N, Hébraud B, Avet-Loiseau H, Roussel M, Huynh A, Gadelorge M, Cordelier P, Klein B, et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 2012; 72:1395 - 406; http://dx.doi.org/10.1158/0008-5472.CAN-11-0188; PMID: 22301101
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2001; 15:1950 - 61; http://dx.doi.org/10.1038/sj.leu.2402295
   PubMed Web of Science ®Google Scholar
• Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012; 136:56 - 68; http://dx.doi.org/10.1016/j.pharmthera.2012.07.004; PMID: 22796518
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607 - 18; http://dx.doi.org/10.1182/blood-2004-01-0037; PMID: 15090448
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Carrasco DR. Role of Wnt Signaling Pathways in Multiple Myeloma Pathogenesis. Advances in Biology and Therapy of Multiple Myeloma: Springer, 2013:85-95.
   Google Scholar
• Yang Y, Mallampati S, Sun B, Zhang J, Kim S-B, Lee J-S, Gong Y, Cai Z, Sun X. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 2013; 333:9 - 17; http://dx.doi.org/10.1016/j.canlet.2012.11.056; PMID: 23333798
   PubMed Web of Science ®Google Scholar
• Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004; 101:6122 - 7; http://dx.doi.org/10.1073/pnas.0305855101; PMID: 15067127
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, Sala R, Mangoni M, Rizzoli V. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67:7665 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-06-4666; PMID: 17702698
   PubMed Web of Science ®Google Scholar
• Qiang YW, Shaughnessy JD Jr., Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008; 112:374 - 82; http://dx.doi.org/10.1182/blood-2007-10-120253; PMID: 18344425
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Ma W, Wang Z-Q, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011; 286:11009 - 20; http://dx.doi.org/10.1074/jbc.M110.180208; PMID: 21189262
   PubMed Web of Science ®Google Scholar
• Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J Jr., Rudikoff S. Wnts induce migration and invasion of myeloma plasma cells. Blood 2005; 106:1786 - 93; http://dx.doi.org/10.1182/blood-2005-01-0049; PMID: 15886323
   PubMed Web of Science ®Google Scholar
• Levina E, Oren M, Ben-Ze’ev A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 2004; 23:4444 - 53; http://dx.doi.org/10.1038/sj.onc.1207587; PMID: 15064706
   PubMed Web of Science ®Google Scholar
• Bueno C, Lopes LF, Menendez P. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Blood Cells Mol Dis 2007; 39:366 - 8; http://dx.doi.org/10.1016/j.bcmd.2007.06.001; PMID: 17632021
   PubMed Web of Science ®Google Scholar
• Yang Y, Mallampati S, Sun B, Zhang J, Kim SB, Lee JS, Gong Y, Cai Z, Sun X. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 2013; 333:9 - 17; http://dx.doi.org/10.1016/j.canlet.2012.11.056; PMID: 23333798
   PubMed Web of Science ®Google Scholar
• Satoh J, Kuroda Y. Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors. Neuropathology 2000; 20:113 - 23; http://dx.doi.org/10.1046/j.1440-1789.2000.00293.x; PMID: 10935448
   PubMed Web of Science ®Google Scholar
• Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A 2000; 97:12103 - 8; http://dx.doi.org/10.1073/pnas.210394297; PMID: 11035789
   PubMed Web of Science ®Google Scholar
• Speranza FJ, Mahankali M, Gomez-Cambronero J. Macrophage migration arrest due to a winning balance of Rac2/Sp1 repression over β-catenin-induced PLD expression. J Leukoc Biol 2013; 94:953 - 62; http://dx.doi.org/10.1189/jlb.0313174; PMID: 23898047
   PubMed Web of Science ®Google Scholar
• Orr SJ, Burg AR, Chan T, Quigley L, Jones GW, Ford JW, Hodge D, Razzook C, Sarhan J, Jones YL, et al. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. PLoS Pathog 2013; 9:e1003357; http://dx.doi.org/10.1371/journal.ppat.1003357; PMID: 23675302
   PubMedGoogle Scholar
• Li W, Henderson LJ, Major EO, Al-Harthi L. IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner. J Immunol 2011; 186:6771 - 8; http://dx.doi.org/10.4049/jimmunol.1100099; PMID: 21562161
   PubMed Web of Science ®Google Scholar
• Liu Z, Brooks RS, Ciappio ED, Kim SJ, Crott JW, Bennett G, Greenberg AS, Mason JB. Diet-induced obesity elevates colonic TNF-α in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J Nutr Biochem 2012; 23:1207 - 13; http://dx.doi.org/10.1016/j.jnutbio.2011.07.002; PMID: 22209007
   PubMed Web of Science ®Google Scholar
• Dai C, Wen X, He W, Liu Y. Inhibition of proinflammatory RANTES expression by TGF-beta1 is mediated by glycogen synthase kinase-3beta-dependent beta-catenin signaling. J Biol Chem 2011; 286:7052 - 9; http://dx.doi.org/10.1074/jbc.M110.174821; PMID: 21189258
   PubMed Web of Science ®Google Scholar
• Pittenger MF. Mesenchymal stem cells from adult bone marrow. Mesenchymal Stem Cells: Springer, 2008:27-44.
   Google Scholar
• Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, Kwak LW, Yi Q. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients’ monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108:4071 - 7; http://dx.doi.org/10.1182/blood-2006-04-016980; PMID: 16917008
   PubMed Web of Science ®Google Scholar